Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

February 9, 2018: By Jon Swedien

Two Pennsylvania investment groups announced Feb. 5 that they have made a $500 thousand joint investment in Ocunova Inc., a spinout from the Penn State University College of Medicine.

Ocunova’s drug candidate, OCU-001, is designed to affect the underlying cause of dry eye disease in diabetes patients, Ocunova CEO Michael Shine said.

A study published in 2014 in the American Diabetes Association’s journal, Diabetes Care, indicated that half of all diabetes patients suffer from dry eye. Study authors noted that nerve disease is a common complication of diabetes, and the most common form, polyneuropathy, can damage corneal nerves, hindering a person’s ability to make tears and slowing the blink rate, causing tears to evaporate.

Ocunova will use the funding to develop OCU-001, the organizations said.

The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and Ben Franklin Technology Partners/CNP made the joint investment.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023